share_log

DaVita | 10-Q: Q3 2024 Earnings Report

DaVita | 10-Q: Q3 2024 Earnings Report

德维特 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/30 05:09

Moomoo AI 已提取核心信息

DaVita reported Q3 2024 consolidated revenues of $3.26 billion, up 2.4% from Q2 2024, with operating income increasing 5.7% to $535 million. U.S. dialysis revenue grew 2.3% to $2.91 billion, driven by increased average reimbursement rates and treatment volumes. Patient service revenue per treatment rose to $394.49, up 1.1% from Q2.The company's international operations expanded significantly, with revenues increasing 6.6% quarter-over-quarter to $258 million. Operating expenses increased, with patient care costs rising 2.0% to $1.89 billion due to higher compensation expenses and wage rates. The company completed $406 million in share repurchases during the quarter, acquiring 2.73 million shares.Looking ahead, DaVita faces ongoing challenges from labor market pressures and supply chain disruptions, particularly following Hurricane Helene's impact on Baxter's manufacturing facility. The company has implemented operational changes including conservation measures and temporary holds on new peritoneal dialysis starts. As of September 30, 2024, DaVita operated 2,660 U.S. dialysis centers and 453 international centers.
DaVita reported Q3 2024 consolidated revenues of $3.26 billion, up 2.4% from Q2 2024, with operating income increasing 5.7% to $535 million. U.S. dialysis revenue grew 2.3% to $2.91 billion, driven by increased average reimbursement rates and treatment volumes. Patient service revenue per treatment rose to $394.49, up 1.1% from Q2.The company's international operations expanded significantly, with revenues increasing 6.6% quarter-over-quarter to $258 million. Operating expenses increased, with patient care costs rising 2.0% to $1.89 billion due to higher compensation expenses and wage rates. The company completed $406 million in share repurchases during the quarter, acquiring 2.73 million shares.Looking ahead, DaVita faces ongoing challenges from labor market pressures and supply chain disruptions, particularly following Hurricane Helene's impact on Baxter's manufacturing facility. The company has implemented operational changes including conservation measures and temporary holds on new peritoneal dialysis starts. As of September 30, 2024, DaVita operated 2,660 U.S. dialysis centers and 453 international centers.
德维特报告2024年第三季度合并营业收入为32.6亿美金，比2024年第二季度增长2.4%，营业收入增加5.7%至53500万美元。美国透析营业收入增长2.3%，达29.1亿美金，主要受益于平均报销率和治疗量的提高。每次治疗的患者服务营业收入上升至394.49美金，比第二季度增加1.1%。公司的国际业务显著扩展，营业收入环比增长6.6%，达25800万美元。营业费用增加，患者护理成本因补偿费用和工资水平提高而上升2.0%，达到18.9亿美金。公司在本季度完成了40600万美元的股份回购，购回273万股。展望未来，德维特面临来自劳动力市场压力和供应链中断的持续挑战，特别是在飓风海伦对百特制造工厂的影响后。公司已实施运营变更，包括节约措施和对新腹膜透析开始的临时暂停。截至2024年9月30日，德维特在美国运营2660家透析中心以及453个国际中心。
德维特报告2024年第三季度合并营业收入为32.6亿美金，比2024年第二季度增长2.4%，营业收入增加5.7%至53500万美元。美国透析营业收入增长2.3%，达29.1亿美金，主要受益于平均报销率和治疗量的提高。每次治疗的患者服务营业收入上升至394.49美金，比第二季度增加1.1%。公司的国际业务显著扩展，营业收入环比增长6.6%，达25800万美元。营业费用增加，患者护理成本因补偿费用和工资水平提高而上升2.0%，达到18.9亿美金。公司在本季度完成了40600万美元的股份回购，购回273万股。展望未来，德维特面临来自劳动力市场压力和供应链中断的持续挑战，特别是在飓风海伦对百特制造工厂的影响后。公司已实施运营变更，包括节约措施和对新腹膜透析开始的临时暂停。截至2024年9月30日，德维特在美国运营2660家透析中心以及453个国际中心。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Basel Medical
    BMGL
    -- 4.555
    布鲁克代尔高级护理
    BKD
    -- 6.150
    The Oncology Institute
    TOI
    -- 1.1400
    费森尤斯医疗
    FMS
    -- 24.780
    Ardent健康伙伴
    ARDT
    -- 13.200
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点